Patients Views & Analysis

Views & Analysis

Patients

How pharma is tackling new direct-to-patient programmes

At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

Patients

Reuters pharma USA 2025 Faruk Abdullah interview

Direct-to-patient is more than just telehealth – with EVERSA...

Hear from EVERSANA's Faruk Abdullah in this video interview as he explains why direct-to-patient strategies go beyond telehealth.

Patients

Unifying observational research with a next-generation virtu...

Observational research is core to drug development, helping researchers understand the natural history of diseases and the real-world impact of treatments on patients.

Patients

Reuters pharmaUS 25 Brian Hilberdink Feature

New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an...

At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.

Patients

Sebastian Vaughan interview at the Eden Project

For the continuum of mental health we need a whole system, h...

If we don’t address the mental health of young people, that mental health challenge will advance into the adult population of tomorrow.

Patients

The growing burden of misinformation: Patients left wonderin...

It’s no secret that challenges related to misinformation are rising, as more people rely on personalised news feeds and non-traditional information channels across the internet and social m

How pharma is tackling new direct-to-patient programmes

Direct-to-patient is more than just telehealth – with EVERSA...

Unifying observational research with a next-generation virtu...

New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an...

For the continuum of mental health we need a whole system, h...

The growing burden of misinformation: Patients left wonderin...

Major trial launched to explore GLP-1 benefit in dementia

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks